Boehringer Ingelheim Deal History & Licensing Activity
Boehringer Ingelheim is a large pharma headquartered in Germany. Over the past three years, Boehringer Ingelheim has been involved in 17 licensing and acquisition transactions, with a primary focus on Other (9 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
9
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
Boehringer Ingelheim Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Boehringer Ingelheim in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Cardiovascular disease collaboration expansion | Variant Bio | Other | Discovery | collaboration | Sep 23, 2026 |
| AI-driven RNA splicing platform (oncology) | Envisagenics | Other | Discovery | collaboration | Sep 22, 2026 |
| CT-155 | Click Therapeutics | Other | Phase 3 | other | Apr 15, 2026 |
| small-molecule immune-disease program | Sitryx Therapeutics | Small Molecules | Preclinical | license | Feb 26, 2026 |
| SIM0709 | Simcere Pharmaceutical Group | Bispecific Antibodies | Preclinical | license | Jan 28, 2026 |
| Undisclosed | Rectify Pharmaceuticals, Inc. | Small Molecules | Preclinical | license | Dec 22, 2025 |
| CDR111 (trispecific M-gager T-cell engager, autoimmune) | CDR-Life, Inc. | Antibodies | Preclinical | license | Nov 4, 2025 |
| Undisclosed | Kyowa Kirin | Small Molecules | Preclinical | license | Oct 30, 2025 |
Boehringer Ingelheim Pipeline Focus
Therapeutic areas and modalities where Boehringer Ingelheim is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Boehringer Ingelheim Strategic Signals
Key indicators of Boehringer Ingelheim's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Boehringer Ingelheim Clinical Pipeline
Boehringer Ingelheim has 50 active clinical trials across 5 development phases.
5
Unknown
25
Phase 1
3
Phase 1/2
5
Phase 2
12
Phase 3
See How Your Asset Matches Boehringer Ingelheim's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Boehringer Ingelheim Licensing & Deal Activity
Boehringer Ingelheim is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 17 deals over the past three years, Boehringer Ingelheim ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Boehringer Ingelheim include Solid Tumors (11 deals and trials), Metabolic (10 deals and trials), Cardiovascular (6 deals and trials), and Oncology (6 deals and trials). In terms of modality, Boehringer Ingelheim has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Boehringer Ingelheim and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Boehringer Ingelheim's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.